Business
Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada
Cannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals to Participate at the LIFT & Co. Conference in Toronto, Canada\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, June 4, 2019\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, June 4, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it will be participating at the LIFT & Co. Conference at the Metro Toronto Convention Centre in Toronto, Canada. \n\n \n \n\n \nMr. Eyal Barad, CEO of Cannabics Pharmaceuticals, will be a participant at the \"Medical Cannabis: More Treatments, Targeted Results and New Clinical Trials\" forum which will take on June 8th, between 2:10pm – 2:55pm.  \n\"This year's conference in Toronto is exciting because it is the largest premier industry business conference event in Canada,\" stated Mr. Barad. \"The event is a great opportunity to meet with fellow industry members, and hear from them about the opportunities and challenges that lay ahead. We are happy to participate and explore potential collaborations with other companies\".\nAbout Lift & Co.Lift & Co. is a publicly traded technology company with a focus on modernizing the cannabis industry. \nAbout Cannabics Pharmaceuticals Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. For more information, please visit www.cannabics.com. \...